C ardiovascular disease is the major cause of morbidity and mortality in the developed world (1) . The major cause of death is associated with atherosclerosis of the coronary, cerebral and renal arteries. Principal risk factors, such as cigarette smoking, hypertension, obesity, and elevated plasma cholesterol levels, may promote the development of vascular disease (2, 3) . Although lifestyle changes and the use of drugs to lower plasma cholesterol levels have had a substantial impact on mortality, atherosclerosis remains the major cause of death (4, 5) .
Atherogenesis is a complex phenomenon involving interplay between inflammatory system components, lipids and the cells of the arterial wall (2, 6) . To provide clues to the interactions involved in atherogenesis, changes in gene expression patterns in the arterial cells during the course of lesion development must be defined. A better understanding of the molecular mechanisms of atherosclerosis will help identify new targets for drug design and may enable early diagnosis for therapeutic intervention.
The early stages of atherosclerosis are thought to represent a protective response to injury or dysfunction of the endothelium that lines the arterial wall (2, 6, 7) . Some of the possible causes of such injury and dysfunction are oxidized and/or elevated LDL (low-density lipoprotein), hypertension, mechanical stress, free radicals (e.g., those produced by cigarette smoking), elevated plasma homocysteine, and infectious microorganisms, such as the herpes virus and Chlamydia pneumoniae (1, 2, (7) (8) (9) (10) . As a consequence of injury, the impaired endothelium initiates an inflammatory reaction. The expression of adhesion molecules and the secretion of cytokines and growth factors are locally increased in the region of injury (6) .
Monocytes and T-lymphocytes infiltrate the injured regions of the vessel wall (9) . The secretion of growth factors and cytokines from these cells initiates the repair process (2) . If repair is not achieved, these cells remain in the sub-endothelial layer, and their numbers increase (9) . In response to the secretions released from cells involved in the inflammatory response, the cells of the arterial wall may proliferate, migrate, differentiate, secrete more growth factors, demonstrate derangements of lipid metabolism, and synthesize connective tissue proteins, such as collagen and fibronectin (11) . These processes contribute to the formation of the neointima, which is derived from the intima and formed in response to endothelial injury or dysfunction. For example, plateletderived growth factor (PDGF), which is produced by cells of the arterial wall (e.g., endothelial cells and vascular smooth muscle cells [VSMCs] ), is one of the most potent chemotactic agents for VSMCs and a potent mitogen for VSMCs (12, 13) . Thus, PDGF secretions may promote the migration and proliferation of VSMCs in the human arterial wall and contribute to the formation of the neointima.
INTERVENTIONAL RADIOLOGY
ORIGINAL ARTICLE TGF/activin signaling pathway activation in intimal hyperplasia and atherosclerosis PURPOSE Intimal hyperplasia and atherosclerosis are the Achilles' heels of vascular interventions. Many cytokines and growth factors have been shown to mediate these pathological processes. There are conflicting data concerning the expression of transforming growth factor-1 (TGF1) antigen in human intimal hyperplasia and atherosclerotic lesions and conflicting views about whether TGF1 is pro-or anti-atherogenic. The presence of TGF1 is not sufficient to infer activation of its signaling pathway because TGF1 may be present in inactive complexes.
MATERIALS AND METHODS
A sensitive immuno-fluorescence assay (cyanine-3 tyramide signal amplification system) was used on human coronary artery and aorta sections with early or advanced stage lesions to detect TGF1, activin, Smad2-P, a marker of the activated TGF1/activin pathway and components of latent TGF complexes.
RESULTS
All antigens were readily detected in the media and neointima of early stage lesions. The levels were either reduced or undetectable in the media of advanced lesions but were increased in the neointima in areas of high cell density. In marked contrast to activin, TGF1 and LAP1 expression levels were closely correlated with Smad2-P throughout the artery wall. CONCLUSION Discrepancies in previous data for TGF1 expression are probably due to assay sensitivity. TGF1, but not activin, expression is consistently correlated with Smad pathway activation in the artery wall. The pattern of Smad2 activation supports a model in which TGF/activin signaling is anti-atherogenic in the media of normal artery walls but is equally compatible with an anti-atherogenic or pro-atherogenic response to TGF/activin in the neointima of lesions.
sion. TGF inhibits the proliferation and migration of vascular smooth muscle cells and maintains their fully differentiated phenotype in vitro (20) . These data, as well as those from in vivo studies (21, 22) , suggest that control of TGF activity is potentially important for homeostasis in the normal arterial vessel wall and that abnormalities in TGF signaling may be important in atherogenesis (20) .
All three mammalian isoforms of TGF are secreted by cells in vitro in inactive forms (23) . The active TGF homodimer (25 kDa), which is noncovalently bound to latency-associated peptides (LAP), constitutes the small latent complex (SLC), and the covalent attachment of the latent TGF-binding protein (LTBP) to LAP forms the large latent complex (LLC [23] ).
There are conflicting data for detecting both the TGF1 antigen and the TGF1 signal-transducing receptors (TGFBRI/TGFBRII hetero-oligomers) in normal arteries and atherosclerotic plaques (24) (25) (26) . Using chromogenic immunoperoxidase, Bobik and colleagues (24) reported significant levels of TGF1 antigen in the neointima of aortic lesions but little or no TGF1 antigen in the media of normal or atherosclerotic aorta. The distribution of both TGFBRI and TGFBRII antigens was highly heterogeneous in the media and neointima of early and advanced stage lesions. It was concluded that only the TGF1 antigen that was co-localized with the expression of both receptors was likely to be functional, and this was only observed in the neointima of Stage II and III lesions (fatty streaks). From these data, it was suggested that TGF1 is likely to be pro-atherogenic. In contrast, McCaffrey and colleagues (26) reported that the pattern of TGF1 antigen expression was similar to that of TGF-BRI and TGFBRII in the fibrous cap of advanced lesions (Stage V). In marked contrast to either study, Ihling and colleagues (25) reported that in 11/11 atherosclerotic human carotid arteries and 5/5 normal coronary arteries both TGFBRI and TGFBRII antigens were highly expressed in all regions of the arterial wall.
These studies did not directly address the question of whether the TGF is active because there is no antibody that distinguishes active TGF homodimers from TGF in SLCs (27) . However, the activation of the Smad signaling pathway by TGF or activin leads to phosphorylation of Smad2 to Smad2-P (23), and Smad2-P levels provide an assay for the activation of the TGF/activin signaling pathway (28) .
In this study, the causes of discrepancies in the detection of TGF1 antigen in previous studies were analyzed by the use of multiple antibodies and detection systems, including Cy-3-TSA, which has been reported to be much more sensitive than chromogenic immunoperoxidase detection (29) . Immuno-Cy-3-TSA assays for TGF1, LAP1, activin-A and Smad2-P were used to determine whether the TGF/activin signaling pathway was activated and whether the expression of any of the antigens examined was correlated with Smad2-P. In addition, these data were correlated with our previously reported expression patterns of LTBP1 (30), which were acquired for the same tissue specimens.
Materials and methods

Section preparation
This study was approved by the Huntingdon Local Research Ethics Committee. Informed consent for the use of coronary and aortic tissue was obtained from 21 patients undergoing cardiac transplantation. Additional normal aorta samples were obtained from two donor hearts. Coronary artery samples (n=22; 17 patients) and aortic samples (n=6, 6 patients; n=2, 2 donors) were mounted in embedding medium and snap-frozen in liquid nitrogen. Tissue sections (8.5 μm) were thaw-mounted onto slides and stored at -85 °C. Lesions in coronary artery and aorta sections were classified according to the criteria of Stary and colleagues (9, 17) using Oil-Red-O, hematoxylin and eosin. Early stage lesions are defined throughout as Stages I-III, and advanced lesions are defined as Stages IV-VI.
Immunohistochemistry
Immunohistochemistry was performed using Cy-3-TSA (NEN Life Sciences, Waltham, Massachusetts, USA). Primary detection antibodies were TGF1, polyclonal affinity purified AF-101-NA (0.5 ng/mL; R&D Systems, Minneapolis, Minnesota, USA) or monoclonal MAB240 (0.62 μg/mL to 25 μg/mL; R&D Systems); LAP1, monoclonal MAB246 (1.25 μg/mL; Interleukin-1 (IL-1) and tumor necrosis factor- (TNF-) secreted by activated monocytes in vitro and in vivo lead to a significant increase in the expression of vascular cell adhesion molecule-1 (VCAM-1 [14] ), intercellular adhesion molecule-1 (ICAM-1 [15] ), and E-selectin in endothelial cells (16) . An increase in the expression of adhesion molecules in turn leads to the recruitment of more inflammatory cells to the injured region (11) . VSMCs may become activated and switch to the dedifferentiated phenotype, which is characterized by increased levels of rough endoplasmic reticulum (17) . Dedifferentiated VSMCs are thought to be important in lesion progression because they proliferate and deposit connective tissue proteins into the extracellular matrix (ECM [6] ).
Platelets are another source of growth factors that may further promote lesion progression (18) . Platelet adhesion to the injured or dysfunctional endothelium leads to the activation and subsequent release reaction of -granules, which contain large concentrations of various growth factors and cytokines (e.g., PDGF [2, 19] ). Although the role of platelets in lesion development is still unclear, it is possible that degranulation and the release of growth factors may influence the cells of the intima. Platelet degranulation may also lead to the migration and proliferation of VSMCs and monocytes in the vascular intima.
If the response to injury or dysfunction of the endothelium is incomplete, the response continues indefinitely. Early stage lesions eventually progress into more life-threatening advanced lesions in which necrosis and accumulation of a lipid core, lesion rupture, and thrombo-embolism are common (2, 17) . Advanced lesions may produce symptoms of angina pectoris or myocardial infarctions, but early stage lesions are almost invariably clinically silent (17, 18) . However, acute rupture of lesions at various stages may lead to near or total artery occlusion (17) .
Vascular stent placement represents one scenario in which the response to injury can presumably lead to restenosis and the sequelae associated with vessel narrowing. Transforming growth factor- (TGF) has been shown to be one of the critical players in mediating intimal hyperplasia and its progres- , 200x (a, e, i, m and c, g, k, o); 120x (b, f, j, n); and 400x (d, h, l, p) . R&D Systems); LTBP1, monoclonal MAB388 (5 μg/mL; R&D Systems) or polyclonal PAB39 (1:800; gift of Prof. K. Miyazono); activin, polyclonal AF338 (5 μg/mL; R&D Systems) specific for activin-A and monoclonal MCA950S (1:200; Serotec, Kidlington, UK) specific for all activins and inhibin; Smad2-P, polyclonal antibody 06-829 (1:400; Upstate Biotechnology, Waltham, Massachusetts, USA); von Willebrand Factor (vWF), polyclonal antibody A0082 (1:500; Dako, Carpinteria, California, USA). All secondary antibodies were biotinylated (1:800; Biotin-SP; Jackson ImmunoResearch, West Grove, Pennsylvania, USA). After treatment with streptavidin-conjugated horseradish peroxidase (1:500; NEN Life Sciences), sections were incubated with Cy-3-TSA reagent for 7 min. TSACy3 staining patterns were compared with those from a chromogenic immunoperoxidase (12-min reaction with Nova-Red substrate kit; Vector, Burlingame, California, USA) reaction, as described previously (24) . To detect nuclei, sections were counterstained with 300 nM DAPI (Molecular Probes) for 10 min and mounted with Prolong-Antifade (Molecular Probes, Invitrogen, Carlsbad, California, USA). For negative controls, an appropriate control IgG (AB-101-C and MAB002, R&D Systems; R5256, Sigma, SigmaAldrich, St. Louis, Missouri, USA) was substituted for the primary antibody. All negative control samples showed no detectable Cy-3 or Nova-Red above background.
Results
TGF1 and LAP1 antigens
Immunofluorescence images of coronary artery sections are compared in Figure 1 for an early stage lesion with a highly cellular neointima (Stage II) and an advanced lesion containing a lipid core (Stage Va). These images are representative of all samples of early and advanced lesions at the same stages. The presence of an intact endothelial layer in all samples was confirmed by immunostaining for vWF.
TGF1 antigen was readily detected in all coronary artery sections using polyclonal antibody AF-101-NA (Fig. 1e-h ), but there was no detectable signal when using the monoclonal antibody MAB240 in any of the sections examined, although the antibody is an effective TGF1 capture agent in ELISAs.
In the early stage lesions, the expression of both TGF1 and LAP1 was much higher in the media than in the endothelial layer and the underlying neointima (Fig. 1a, b, e and f) . TGF1 and LAP1 antigens were present both in the cytoplasm of the smooth muscle cells and in the extracellular matrix. Similar distributions of TGF1 and LAP1 antigen were also detected in the media of all of the advanced lesions ( Fig. 1d and  h ), but the expression levels of both antigens were reduced as compared to the media of the early stage lesions.
The expression of both TGF1 and LAP1 antigens was much higher in the cellular regions (e.g., the fibrous cap) of the advanced lesions than in the neointima of the early stage lesions (compare Fig. 1c , g with a, e). TGF1 and LAP1 antigens in these regions were mainly extracellular, and minimal antigen was detected in the cytoplasm. Regions of low cell density in the neointima showed reduced levels of expression for both antigens.
The expression patterns of TGF1 and LAP1 antigens were very similar within each stage of the early and advanced lesions in coronary artery sections. However, in a previous study of the aorta using chromogenic immunoperoxidase detection, no TGF1 antigen was detected in the media of early or advanced stage lesions (24) . We examined aortic sections from two donors and four recipients (all normal artery or early stage lesions) using the same antibodies and Cy-3-TSA detection system used for the coronary artery sections. Similar patterns of TGF1 (and of LAP1, Smad2-P, activin-A and LTBP1 antigens) were detected in the media of the normal aorta sections as in the early stage lesions of the coronary artery sections (Figs. 1 and 2) . In contrast, when TRITC-labeled secondary antibody was used in place of the Cy-3-TSA, TGF1 was only weakly detected above background autofluorescence (not shown); with Nova-Red chromogenic immunoperoxidase, TGF1 was barely detectable, if at all (compare Fig. 1a, c with b, d) . Thus, the detection of TGF1 in the media is critically dependent on both the antibody and the sensitivity of the detection system used.
Smad2-P antigen
The TGF1 antibodies in ELISAs do not distinguish between active TGF1 homodimers and TGF1 in SLCs (27) ; hence, antigen detection does not identify active TGF1. Smad2-P expression was therefore examined to determine whether the TGF1 detected in sections might be active. For the early stage coronary artery lesions, Smad2-P antigen expression was much higher in the media than in the neointima (Fig.  1i and j) , and a similar pattern was observed in the early stage lesions in aorta sections. However, in the media of the advanced lesions, Smad2-P was reduced as compared to the levels detected in the media of the early stage lesions (compare Fig. 1j and l) , whereas Smad2-P expression was increased in the neointima of the advanced lesions in regions of high cell density (compare Fig. 1i and k) . The pattern of Smad2-P expression was therefore strongly correlated with TGF1 and LAP1 in the media and neointima of both early and advanced stage lesions. Smad2-P was detected in both the cytoplasm and nucleus at all sites.
Activin
The above data are consistent with regulation of the Smad2 pathway by TGF1. However, activins also regulate the same pathway, and the presence of activin antigen has been reported in the vessel walls of human aortas (31) . We therefore examined the expression of activins in the coronary artery sections to compare with the patterns of Smad2-P expression. Antibodies to the A subunit (binding all activins and inhibin) and antibodies to the active A dimer (binding activin-A only) showed very similar patterns of expression, consistent with previous data showing that activin-A is the major activin antigen detected in the human aorta (31) .
In the early stage lesions, activin expression was much higher in the media than in the neointima, where the antigen was barely detectable (Fig. 1m  and n) . However, in the media and the neointima of the advanced lesions, activin expression was greater than the corresponding levels detected in the media and neointima of the early stage lesions (compare Fig. 1m, n with o, p) . In the advanced lesions, activin in the neointima was mostly detected in regions of high cell density (e.g., fibrous caps). All of the activin detected was both cytoplasmic and extracellular.
The relative levels of activin and Smad2-P expression were inversely related in the media of the advanced lesions as compared with the media of the early stage lesions, and there was no consistent correlation between activin and Smad2-P expression, in marked contrast to TGF1.
LTBP1 antigen
We previously showed (30) that the LTBP1 antigen is easily detectable in the media of early stage lesions but is not detected in the media of advanced lesions using either the monoclonal or polyclonal antibody. Very high levels of LTBP1 were consistently detected in the endothelial layer, overlying lower levels of uniform expression in the neointima of early stage lesions. In the neointima of advanced lesions, LTBP1 antigen levels were very heterogeneous and were mainly restricted to areas of high cell density (e.g., the fibrous cap), with intense staining at the endothelial surface.
TGF1 and LAP1 protein expression in both the early and advanced stage lesions was closely correlated with Smad2-P levels, whereas the expression of LTBP1 was distinct. In particular, there was no correlation between TGF1 and LTBP1 at the luminal surface of the early or advanced stage lesions, whereas LTBP1 was very strongly expressed. Conversely, LTBP1 was not detectable in the media of the advanced lesions, whereas low levels of TGF1 were observed.
Discussion
TGF1 antigen expression in the coronary artery and aorta
The consistency of the data for antigen detection obtained for different lesions of the same stage in this and previous studies (24) (25) (26) suggests that sample heterogeneity is unlikely to be a major cause of the discrepancies in antigen detection. However, we have shown that the ability to detect TGF1 antigen in the media of early lesions, for example, depends critically on the sensitivity of the detection system. TGF1 antigen was readily detectable in the media using the Cy3-TSA detection system (see Fig. 2a) ; however, it was much harder to detect above background autofluorescence using TRITC-labeled secondary antibodies, and it was at the limit of detection when using the chromogen immunoperoxidase detection technique used in previous studies (24) (25) (26) . Furthermore, wide variations in the ability of different antibodies to detect TGF1 antigen in the artery wall are apparent from the inability of a monoclonal antibody to detect TGF1 at sites in adjacent sections where the polyclonal antibody was effective. The consistency of data between studies is therefore likely to depend on the use of appropriate antibodies and detection systems for TGF and related antigens.
Activation of the Smad signaling pathway
Smad2-P is generated in response to TGF and activin signaling (23) . Our data show that, in marked contrast to activin, the expression patterns of TGF1 and LAP1 antigens were closely correlated with each other and with Smad2-P antigen expression in the early and advanced stage lesions. The data suggest that TGF1, rather than activin, is the major activator of the pathway in the media of advanced lesions, but it does not allow the contributions of the two ligands to the production of Smad2-P to be distinguished elsewhere.
The close correlation between TGF1 and LAP1 antigen expression is consistent with the ability of the TGF1 antibodies to detect the active TGF1 homodimer and TGF1 in SLCs in vitro with similar sensitivity. The correlation of both antigens with Smad2-P is most simply accounted for by assuming that TGF1 activity is determined mainly by the amount of SLC produced, rather than by variations in the SLC proteolytic activation rate.
As we showed previously (30) , there was a marked difference in the expression pattern of LTBP1 antigen as compared with LAP1 or TGF1, particularly at the luminal surface of both the early and advanced stage lesions; consequently, no consistent correlation between LTBP1 expression and Smad2-P was found. We also showed previously that the in situ hybridization patterns for LTBP1 mRNA do not account for the patterns of protein expression (30) . Furthermore, the LTBP1 protein at the luminal surface of lesions does not appear to be a component of LLCs because the LAP1 and LTBP1 expression patterns are very different, although the LAP1 antibody recognizes LAP1 in both LLCs and SLCs (27) . The data do not allow for a clear distinction between models in which LTBP1 is produced independently of SLC components at the luminal surface of the neointima and those in which LTBP1 from SLCs is slowly degraded and therefore accumulates at some sites in the neointima, relative to LAP1 and TGF1 antigens. Inefficient conversion of LLCs to SLCs and TGF in the neointima may result from insufficient proteolytic activity in the neointima as compared with the media. However, this difference may also be due, in whole or in part, to the switch to LTBP1∆41 isoform expression, if this isoform is relatively resistant to proteolysis (32) . The deposition of LTBP1 from the circulation may also contribute to the high levels detected at the luminal surface.
Implications for atherogenesis
It has been suggested that the increase in the TGF1 antigen, together with the presence of the TGF1 signaling receptors detected in the neointima of advanced lesions, indicates that TGF is pro-atherogenic (24-26). However, it seems unlikely that the role of TGF in atherogenesis can be deduced simply from the presence of TGF antigen and its receptors. Furthermore, our finding that TGF1 antigen expression is closely correlated with Smad2 signaling pathway activation in the media and neointima of both early and late stage lesions does not fully resolve this issue. For example, it is possible that the expression of TGF1 in the media of early stage lesions and the reduced levels in advanced lesions reflect a decreased anti-atherogenic effect of TGF1 in the media as lesions develop. In this model, the increases in TGF1 antigen and the activation of Smad signaling in the neointima of advanced lesions may represent a compensatory protective mechanism against lesion development (e.g., by strengthening the fibrous cap, where there is strong Smad signaling) that is overridden by atherogenic stimuli as lesions develop. Alternatively, the increased TGF1/activin expressed in the neointima of lesions may represent a contributory mechanism to lesion development, as suggested previously (24) .
Two observations suggest that the former view is more likely. It seems very unlikely that the TGF1/activin and Smad2 signaling clearly detected in the media of normal coronary artery and aorta contribute to atherogenesis in the normal vessel wall. Similarly, TGF1 antigen expression has been observed at high levels in mouse and rat arteries, which are not normally susceptible to atherogenesis (21, 33) . It is more plausible that there are mechanisms to protect the normal artery wall against atherogenic stimuli, analogous to the anti-thrombotic mechanisms described for the arterial endothelium. Furthermore, we have shown that the aortas of mice heterozygous for the TGF1 allele are susceptible to lipid lesion formation when fed a high-fat diet, whereas their wild-type controls are resistant (22) . The reduced level of TGF1 antigen in the aortic wall of heterozygous mice is therefore correlated with increased susceptibility to lipid lesion formation. The correlation between antigen and Smad2-P patterns in human arteries cannot definitively resolve whether TGF is pro-or antiatherogenic or indeed whether TGF has any effect in modulating lesion development, but the evidence points more plausibly to a protective effect.
